Brief: Silo Pharma Says IND Submission For Intranasal SPC-15 Treatment Expected In 2025
02/01/2025 16:17
Jan 2 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA INC: IND SUBMISSION FOR INTRANASAL SPC-15
TREATMENT
EXPECTED IN 2025
Source text: ID:n0001213900-25-000191
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement